United Capital Financial Advisors LLC Acquires New Shares in Zimmer Biomet Holdings, Inc. $ZBH

United Capital Financial Advisors LLC acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,602 shares of the medical equipment provider’s stock, valued at approximately $654,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dodge & Cox lifted its stake in shares of Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock valued at $2,113,736,000 after purchasing an additional 290,676 shares during the last quarter. BlackRock Inc. purchased a new stake in Zimmer Biomet in the 2nd quarter valued at about $1,344,282,000. State Street Corp raised its holdings in Zimmer Biomet by 2.3% in the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after buying an additional 195,214 shares during the period. Franklin Resources Inc. lifted its position in Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after buying an additional 2,017,857 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Zimmer Biomet by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after buying an additional 36,611 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Citigroup dropped their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Stifel Nicolaus boosted their target price on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Sanford C. Bernstein upped their price target on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Stock Down 0.7%

Shares of ZBH opened at $100.19 on Tuesday. The company’s 50-day simple moving average is $94.14 and its 200-day simple moving average is $91.52. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88. The stock has a market capitalization of $19.11 billion, a PE ratio of 24.38, a P/E/G ratio of 2.74 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.